Navigation Links
New transplantation criteria for liver cancer patients
Date:7/28/2010

Researchers at the University of California, San Francisco propose that treatments used on liver cancers beyond the established Milan criteria for liver transplantation may be appropriate for all patients with hepatocellular carcinoma (HCC) who are listed for transplantation. Full details appear in the August issue of Liver Transplantation, a journal published by Wiley-Blackwell on behalf of the American Association for the Study of Liver Diseases (AASLD).

According to the American Cancer Society, about 90% of adult primary liver cancers are hepatocellular carcinomas. In 2009, an estimated 22,620 adults in the U.S. were diagnosed with primary liver cancer with 18,160 deaths expected to occur this year from HCC. Liver cancer is the sixth most common cause of cancer death among men, and ninth most common cause of cancer death among women.

Liver transplantation is an important treatment option for selected patients with non-resectable HCC. The Milan criteria provide guidelines to qualify HCC patients for liver transplantation and include one tumor smaller than 5 cm or up to 3 tumors smaller than 3 cm, no extrahepatic manifestations, and no vascular invasion. The Milan criteria were adopted because it identified a population with excellent outcome potential following transplantationroughly equivalent to patients transplanted without HCC. However, HCC incidence is expected to increase and researchers are investigating whether the criteria for liver transplantation should be expanded to make even more patients eligible.

The San Francisco researchers suggest that the Milan and other criteria have proved inadequate. Team leader Dr. John Roberts explains, "It has not been shown there is any particular size of tumor that represents a 'no risk' of recurrence, at least among those tumors that can be detected radiologically. Further, the degree of risk is not the same for all patients within the Milan criteria."

Dr. Roberts points out that tumor size and number are only surrogate markers for underlying tumor biology and that using another markertumor behavior over timeallows the biology of the tumor to become apparent, dictating the most appropriate treatment strategy.

The UCSF team has taken a 'down staging' approach for patients with large tumors. This involves radiofrequency ablation, chemoembolization or both to control the tumor and then a requisite waiting period to determine tumor biology over time as the development of extra-hepatic or intra-hepatic spread is observed. This paradigm results in about 30% of the patients being ineligible for transplantation because of HCC progression, but those who make it to transplantation have an excellent outcome as compared to patients transplanted with tumors beyond the Milan criteria who are not treated. The median time between the first ablative procedure and transplantation was 8.2 months with a range of 3-25 months. This approach suggests that the test of time may be the surest method to select patients with HCC who are destined to have good transplant outcomes. Dr. Roberts argues that this approach, ablating the tumor and waiting, should be expanded to all patients listed for transplantation with hepatocellular carcinoma as the test of time can eliminate from transplantation patients whose disease is likely to recur after transplantation.

"Our experience with ablative treatment and then observation suggests that the ultimate outcomes of transplantation are not dependent on the primary tumor but more on time spent waiting for transplantation," Dr. Roberts concluded. "It would seem logical that smaller and/or fewer tumors, though more unlikely to have spread, would also benefit from a period of time if the primary tumor can be controlled. The waiting period may be able to decrease the 10% recurrence rate seen in patients transplanted within Milan."


'/>"/>

Contact: Dawn Peters
healthnews@wiley.com
781-388-8408
Wiley-Blackwell
Source:Eurekalert

Related medicine news :

1. Stem cell transplantation of therapy-resistant chronic leukemia successful
2. Combination of Meniscus Allograft Transplantation and Repair of Articular Cartilage May Slow the Progression of Arthritis in the Knee
3. The experience of arterial reconstruction in adult-to-adult living donor liver transplantation
4. African-Americans and women are less likely to undergo bone marrow transplantation
5. Study examines global availability of treatment involving transplantation of blood stem cells
6. Cedars-Sinai heart transplantation tip sheet
7. Cell Transplantation Eyed as Treatment for Cerebral Palsy
8. Living donor exchange poses new option for liver transplantation
9. Novel Parkinson's Treatment Strategy Involves Cell Transplantation
10. Fewer platelets could be used for some cancer and bone-marrow transplantation patients
11. New Criteria for Alzheimers Diagnosis Proposed
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/23/2017)... ... March 23, 2017 , ... The IoT (Internet of Things) is ... making a huge impact on businesses and individual consumers alike. Laboratories can maximize ... have a value anywhere from $4 trillion to $11 trillion dollars by the year ...
(Date:3/23/2017)... ... March 23, 2017 , ... ... serving the families and businesses of the Norwalk and Vermillion areas, celebrates ... Recovery Center (N.O.R.A.) is a nonprofit, community-based substance abuse prevention and peer ...
(Date:3/23/2017)... ... 23, 2017 , ... The StayWell Company announced today that ... covers StayWell’s asthma, coronary artery disease, congestive heart failure, chronic obstructive pulmonary disease, ... excellent programs for the delivery and improvement of disease management and that meet ...
(Date:3/23/2017)... ... ... The TouchPoint Solution, home of Buzzies *, is boosting the Arizona economy ... change the way we interact with stress and live our day-to-day lives,” said Dr. ... December 2016, The TouchPoint Solution has sold more than $750,000 in product sales. The ...
(Date:3/23/2017)... ... 23, 2017 , ... After raising more than $1.135 million ($1,479,231 AUD) from ... pillow in crowdfunding history, has established a U.S. Headquarters in New York City, ... Americans. , “We’re excited to be operating on U.S. shores, where most of our ...
Breaking Medicine News(10 mins):
(Date:3/23/2017)... March 23, 2017  Interpace Diagnostics Group, Inc. ... fully integrated commercial company that provides clinically useful ... that it has entered into agreements to successfully ... Shareholders ("RedPath") and concurrently terminate its royalty and ... secured debt to RedPath amounting to $9.34 million ...
(Date:3/23/2017)... DENVER , March 23, 2017  Drug ... pain medication misuse and deadly overdoses. A new ... Health Solutions, www.cordantsolutions.com , reports more detailed ... tests, which can potentially improve therapy adherence, patient ... The Cordant Comprehensive Oral fluid Rx Evaluation ...
(Date:3/23/2017)... , March 23, 2017 /PRNewswire/ - INVICTUS MD ... IVITF; FRA: 8IS) Invictus MD announces that AB Laboratories ... in its licensed production facility under the Access to ... Hamilton, Ontario . The ... in October 2016, is currently operating at half capacity, ...
Breaking Medicine Technology: